Breviscapine nanoparticles and preparation method thereof
Through the non-aqueous anti-solvent precipitation method and the atmospheric drying process, the high cost and complexity of preparing lantern nanoparticles in the prior art was solved, and efficient and low-cost nanoparticles were achieved, which improved the solubility of the drug and Dissolution performance, suitable for large-scale production.
Patent Information
- Application Number
- CN202310220434.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-09
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-03-09
AI Technical Summary
The prior art requires the use of high energy-consuming equipment and a large number of auxiliary materials when preparing lantern nanoparticles, which leads to high costs, complex production and difficult to promote application, and the improvement of solubility and dissolution of insoluble drugs is limited.
The non-aqueous anti-solvent precipitation method and normal pressure or reduced pressure drying process are used to prepare the nanosuspension nanosuspension and nanoparticle powder. Conventional equipment is used to reduce the amount of auxiliary materials, simplify the process flow, and improve the stability and solubility of nanoparticles.
It realizes the preparation of nanoparticles at low cost, simple and efficiently, improves the solubility and dissolution performance of drugs, reduces drying and aggregation behavior, and is suitable for large-scale production and promotion and application.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicines, and in particular to scutellarin nanoparticles and a method for preparing the scutellarin nanoparticles. Background Art
[0002] Breviscapine is extracted and refined from Breviscapine, and mainly contains flavonoid active ingredients such as scutellarin. Breviscapine has the effects of reducing cerebrovascular resistance, increasing cerebral blood flow, dilating cardiovascular and cerebrovascular vessels, improving microcirculation and anti-platelet aggregation. Breviscapine is a commonly used drug for the clinical treatment of cardiovascular and cerebrovascular diseases. The main marketed preparations include tablets, granules, dispersible tablets, injections, sterile powder for injection, etc. However, Breviscapine has extremely poor water solubility and fat solubility, and low oral bioavailability, which seriously restricts the clinical efficacy.
[0003] In pharmacy, new formulation technologies such as molecular inclusion complexes, solid dispersions, and nanocarriers (liposomes, nanoemulsions, solid lipid nanoparticles, polymer micelles, nanoparticles...) are usually used to improve the solubility of poorly soluble drugs and enhance the dissolution and absorption of drugs. These technologies have been tried for the treatment of breviscapine, and its solubility and dissolution properties have been improved to varying degrees. However, the above technologies generally require the addition of a large amount of carriers or excipients to form, resulting in limited drug loading in the finished product and increased clinical application doses; or they involve more complex or special process methods and low yields, which are not conducive to industrial production and promotion and application.
[0004] Among many new formulation technologies, nanocrystal technology has received extensive attention. This technology uses surfactants or polymers as stabilizers to disperse drug particles in water. It is a submicron colloidal dispersion system prepared by self-assembly technology or crushing technology, namely nanosuspension. After adding a suitable protective agent and drying, nanocrystalline powder can be further obtained; the particle size of nanosuspension or redispersed nanoparticles is generally in the range of 10~1000nm. Nanocrystal technology can improve the saturated solubility of drugs, accelerate dissolution and improve bioavailability. It is also suitable for water-insoluble drugs and drugs that are both insoluble in water and oil (such as breviscapine). In addition, nanosuspensions and nanocrystals can be used as formulation intermediates to further prepare a variety of dosage forms and formulation products suitable for intravenous injection, oral administration, pulmonary inhalation, local injection, transdermal administration, and ophthalmic administration. Among them, nanosuspensions may produce unstable phenomena such as crystal growth, aggregation and sedimentation, degradation and deterioration during the storage process, while nanocrystals in a dry powder state are more stable and easier to store, transport and reprocess.
[0005] In order to obtain nanosuspensions of poorly soluble drugs, two approaches are often used: one is top-down, that is, various grinding techniques are used to gradually reduce the particle size of drug particles to less than 1000nm, often in combination with high-speed shearing, medium grinding, high-pressure homogenization and other processes. The required equipment is expensive, energy consumption is high, and loss is large. The second is bottom-up, that is, the drug is first dispersed in an appropriate solvent (as a good solvent) to form a solution, and then the anti-solvent precipitation or drying process is used to quickly precipitate the drug and control the particle size within 1000nm. The anti-solvent precipitation process often uses an aqueous medium containing polymers, surfactants and their mixed components as an anti-solvent, and the drying process uses high-voltage electrostatic or jet spray. The obtained nanosuspension can be further prepared into a dry powder by spray drying or freeze drying, but it is usually necessary to add a large amount of protective agent or stabilizer to avoid or reduce the aggregation and increase of particles during the drying process, which greatly reduces the drug loading and increases the production cost.
[0006] Prior art CN201110163297 discloses a method for preparing hydrophobic nanoparticle drug solid dispersion by high-voltage electrostatic spraying, CN201310739437 discloses a scutellarin composite nanoparticle and its preparation method, and CN01100676 discloses a nano-scutellarin preparation drug and its preparation method, and specifically provides a technical solution for scutellarin nanoparticles. However, the above-mentioned prior art all requires the use of special devices such as electrostatic spraying and supersonic instantaneous jet spray drying, and cannot be achieved with the help of conventional equipment.
[0007] Prior art CN201810068860 discloses a supercritical anti-solvent fluidized coated nanoparticle and a preparation method thereof, and CN201810068841 discloses a supercritical anti-solvent breviscapine nanoparticle and a preparation method thereof, and specifically provides a technical solution for breviscapine nanoparticles. However, the above-mentioned prior art all requires the use of supercritical carbon dioxide fluid and corresponding special devices, and cannot be achieved with the help of conventional solvents and conventional equipment.
[0008] Prior art CN201610319820 discloses a dual-drug nanocomposite particle of scutellarin and notoginseng total saponin and a preparation method thereof, wherein notoginseng total saponin is used as a stabilizer, and a nanosuspension is prepared by high-speed shearing and high-pressure homogenization in sequence, and a protective agent is further added to obtain a crystalline powder by spray drying or freeze drying; CN201810069497 discloses a scutellarin nanoparticle and a preparation method thereof, wherein Tween 80 or sodium dodecyl sulfate is used as a stabilizer, and a nanosuspension is prepared by a medium grinding process, and a protective agent is further added to obtain a crystalline powder by freeze drying; CN202011128043 discloses a preparation method and application of small-particle-size polyhydroxy traditional Chinese medicine active ingredient nanoparticles, wherein povidone is used as a stabilizer, and a nanosuspension is prepared by a high-pressure homogenization or medium grinding process, or a protective agent is further added to obtain a crystalline powder by spray drying or freeze drying, and a technical solution for scutellarin nanoparticles is specifically given. The prior art "Nose-to-Brain Delivery by Nanosuspensions Based in situ Gel for Breviscapine" (Yingchong Chen et al., International Journal of Nanomedicine, 15: 10435-10451, 2020) discloses a nasal in situ gel preparation containing breviscapine nanosuspension, and its preparation method and application; it first uses Tween 80 as a stabilizer, and successively obtains a nanosuspension by high-speed shearing (22000rpm for 3 minutes) and high-pressure homogenization (pressure 200~1000bar, total cycle number 100). Under a transmission electron microscope, the particles are irregular short rods with a length of about 500nm; then mannitol is added as a protective agent, and a crystalline powder is obtained by spray drying. Under a scanning electron microscope, the particles are spherical with a diameter of 1~5μm and a rough surface. However, the above-mentioned existing technologies all belong to top-down strategies, which must rely on high-energy-consuming equipment such as high-pressure homogenizers and ball mills, and the resulting nanosuspension needs to be added with a large amount of protective agent to ensure redispersibility after the subsequent drying process.
[0009] The prior art "Preparation of Breviscapine Nanosuspension and Its Pharmacokinetic Study in Rats" (She Zuoyan et al., Chinese Natural Medicine, 5 (1), January 2007) discloses an "emulsification-diffusion method" for preparing Breviscapine nanosuspension; specifically, the ethyl acetate-acetone (8:2) solution of Breviscapine is added to an aqueous medium (containing Tween 80 and Poloxamer 188 as stabilizers) under magnetic stirring conditions, and the organic solvent is evaporated after continuous stirring for 8 hours to obtain Breviscapine nanosuspension, with an average particle size of about 300 nm. The above prior art belongs to the bottom-up approach, and must rely on the emulsion forming and solidification process to finally form particles. In order to ensure the acquisition of nano-scale particles, the emulsion must have a large enough dispersion degree, and conventional dispersion methods are difficult to ensure the uniformity of the emulsion; at the same time, the technology requires Breviscapine to be dissolved in the emulsion, which not only limits the types of emulsion solvents that can be selected and the range of drug concentration, but also requires the use of a larger amount of organic solvent, and it is difficult to recycle the organic solvent.
[0010] Prior art CN201610038534 discloses a long-acting sustained-release microparticle carrying breviscapine nanocrystals and a preparation method thereof, and specifically provides a technical solution for breviscapine nanocrystals; a dimethyl sulfoxide solution of breviscapine is injected into water under ultrasonic or high-speed shearing conditions to prepare a nanosuspension. Prior art "Preparation, Characterization, and Evaluation of Breviscapine Nanosuspension and Its Freeze-Dried Powder" (Ting Zhang et al., Pharmaceutics, 14, 923, 2022) discloses a specific method for preparing breviscapine nanosuspension by an ultrasound-assisted-antisolvent precipitation process; first, a dimethyl sulfoxide solution of breviscapine is injected into an aqueous medium (containing soybean lecithin as a stabilizer) under ultrasonic conditions to prepare a nanosuspension; then 7% mannitol (w / v) is added as a protective agent, and a crystalline powder is obtained by freeze-drying; the obtained nanoparticles are spherical with a diameter of about 300nm under transmission and scanning electron microscopes. The above-mentioned existing technologies all adopt the anti-solvent precipitation method to prepare the breviscapine nanosuspension, which belongs to the bottom-up approach. However, the anti-solvent used is limited to water or an aqueous medium containing a stabilizer, which brings many inconveniences to the subsequent drying process. In addition, a large amount of protective agent must be added during the drying process to avoid excessive aggregation and enlargement of particles.
[0011] The breviscapine nanosuspension described in the present invention is prepared based on a non-aqueous anti-solvent precipitation process, and its dry nanoparticle powder is prepared based on a normal pressure or reduced pressure drying process. The equipment involved is all commonly used equipment in pharmaceutical companies, with mild conditions, simple and controllable, short cycle, low energy consumption, and is particularly suitable for large-scale production, and has a high value for promotion and application. Summary of the invention
[0012] The purpose of the present invention is to provide a simple, efficient and low-cost method for preparing breviscapine nanosuspension and nanoparticle powder thereof. The above preparation method can reduce costs and improve efficiency while meeting the requirements of nano-scale particles, or reduce the amount of auxiliary materials under the condition of the same dosage.
[0013] Another object of the present invention is to provide a preparation process for improving the dissolution and absorption and penetration properties of breviscapine, and enhancing the stability of nanoparticles and inhibiting their drying aggregation behavior. The preparation method is simple, does not require special equipment, and the proportion of auxiliary materials is small and they are cheap and easily available.
[0014] Specifically, the present invention provides the following technical solutions:
[0015] A breviscapine nanoparticle powder, comprising breviscapine and a dispersant, wherein the weight ratio of breviscapine to the dispersant is in the range of 1:0.5 to 1:5;
[0016] Preferably, the weight ratio of breviscapine to the dispersant is 1:1 to 1:3;
[0017] More preferably, the weight ratio of breviscapine to the dispersant is 1:1.
[0018] The breviscapine nanoparticle powder provided by the present invention is in an amorphous state and has no obvious characteristic diffraction peak under the detection of a powder X-ray diffractometer.
[0019] The breviscapine nanosuspension provided by the invention has an average particle size of less than 800 nm and is highly uniform. The nanoparticle powder obtained after drying has an average particle size of less than 1000 nm after adding water and redispersing.
[0020] The invention also provides a method for preparing the breviscapine nanosuspension, namely, an anti-solvent precipitation method.
[0021] Specifically, breviscapine is dissolved in a good solvent, and a dispersant is also dissolved in a good solvent or a poor solvent. Then, the breviscapine solution is dispersed in the poor solvent with the assistance of vortexing, stirring, ultrasound, high-speed shearing and the like.
[0022] The good solvent used is dimethyl sulfoxide, N,N-dimethylformamide and a mixed solvent containing other solvents; preferably, the good solvent is dimethyl sulfoxide.
[0023] The poor solvent used is dichloromethane, acetone, ethanol, dioxane and a mixed solvent thereof; preferably, the poor solvent is dichloromethane.
[0024] The dispersant used is povidone, poloxamer and a mixture thereof; preferably, the dispersant is povidone.
[0025] During the preparation process, the dispersant can be dissolved together with the drug in a good solvent, or the dispersant can be dissolved in a poor solvent; preferably, the dispersant should be dissolved in a poor solvent.
[0026] The present invention also provides a method for further preparing nanoparticle powder based on the breviscapine nanosuspension, wherein the obtained nanosuspension is appropriately concentrated, the poor solvent is recovered, and the dried crystalline powder is obtained by further natural evaporation, drying or reduced pressure drying.
[0027] In summary, the inventors have found through unexpected research that, through the anti-solvent precipitation method, using a low-boiling non-aqueous solvent as an anti-solvent and supplemented with a small amount of dispersant, a highly uniform particle size of breviscapine nanosuspension can be easily obtained, and after simple drying, a nanoparticle powder with good redispersibility can be obtained, which not only does not require special excipients, has a high drug loading, and saves costs, but also greatly simplifies the process, facilitates large-scale production and popularization and application. In addition, it can significantly increase the solubility of the active ingredient and accelerate in vitro dissolution. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The micrograph of the breviscapine nanosuspension in Examples 1, 2, and 3 (left) and its appearance after being placed for 12 hours (right).
[0029] Figure 2 The micrographs of the scutellariae suspensions in Comparative Examples 1, 2, 3, and 4 (left) and their appearance after being placed for 12 hours (right).
[0030] Figure 3 The particle size distribution diagram of the scutellarin nanosuspension and the corresponding dry powder after redispersion in Example 1 (A is the nanosuspension, B is the suspension of the dried nanoparticles redispersed with water), and the scanning electron microscope images of the scutellarin bulk drug and its nanoparticle powder (C is the bulk drug, D is the nanosuspension, and E and F are both dry nanoparticle powders).
[0031] Figure 4 The X-ray diffraction spectrum (A) and differential scanning calorimetry spectrum (B) of the dried nanoparticle powder of scutellarin in Example 1, the equilibrium solubility diagram (C) and in vitro dissolution curve diagram (D) of the scutellarin raw material and its nanoparticle powder are shown in FIG.
[0032] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Implementation
[0033] Example 1: Weigh the scutellarin raw material, add an appropriate amount of dimethyl sulfoxide, and vortex or ultrasonicate to completely dissolve it; the above solution (1 part) is fully mixed with a dichloromethane solution (40 parts) containing povidone (equal to scutellarin) under ultrasonic conditions to obtain a scutellarin nanosuspension; the obtained suspension is transferred to a rotary evaporator, and most of the dichloromethane is recovered under reduced pressure at 40°C. The obtained concentrated solution (5 parts) is spread on a tray and placed in a fume hood overnight; the tray is then transferred to a reduced pressure drying oven at 60°C and dried for 2 hours, and the scutellarin nanoparticle powder is obtained by crushing and passing through a 100-mesh sieve.
[0034] Example 2: The scutellarin nanosuspension was prepared by vortex-assisted dispersion, and the rest was the same as Example 1.
[0035] Example 3: Poloxamer was used as a dispersant, and the concentrated suspension obtained was dried under reduced pressure at 60°C to obtain a dry powder. The rest was the same as in Example 1.
[0036] Example 4: The ratio of drug to dispersant is 1:2, the ratio of good solvent to poor solvent is 1:20, the concentrated suspension obtained is dried under reduced pressure at 60°C to obtain dry powder, and the rest is the same as Example 1.
[0037] Embodiment 5: adopt ethanol as poor solvent, and the rest is the same as embodiment 1.
[0038] Example 6: Povidone and poloxamer are used as mixed dispersants (ratio of 1:1), the ratio of drug to dispersant is 1:5, and both are dissolved in a good solvent. N,N-dimethylformamide is used as a good solvent, ethanol is used as a poor solvent, and the ratio of good solvent to poor solvent is 1:10. The obtained concentrated suspension is dried under reduced pressure at 60°C to obtain a dry powder, and the rest is the same as Example 1.
[0039] Example 7: Poloxamer is used as a dispersant, the ratio of drug to dispersant is 1:0.5, N,N-dimethylformamide is used as a good solvent, the ratio of good solvent to poor solvent is 1:80, and the rest is the same as Example 1.
[0040] Example 8: The ratio of drug to dispersant is 1:3, dimethyl sulfoxide and N,N-dimethylformamide are used as mixed good solvents (ratio of 1:1), dioxane is used as poor solvent, the ratio of good solvent to poor solvent is 1:60, magnetic stirring is used to assist dispersion to prepare breviscapine nanosuspension, the concentrated suspension is dried at 60°C under reduced pressure to obtain a dry powder, and the rest is the same as Example 1.
[0041] Example 9: Poloxamer was used as a dispersant, the ratio of drug to dispersant was 1:2, dimethyl sulfoxide and N,N-dimethylformamide were used as a mixed good solvent (ratio of 1:1), acetone was used as a poor solvent, the ratio of good solvent to poor solvent was 1:30, high-speed shearing method was used to assist dispersion to prepare breviscapine nanosuspension, the concentrated suspension was dried at 60°C under reduced pressure to obtain a dry powder, and the rest was the same as Example 1.
[0042] Comparative Example 1: Weigh the scutellarin raw material, add an appropriate amount of dimethyl sulfoxide, and vortex or ultrasonicate to completely dissolve it; the above solution (1 part) is fully mixed with an aqueous solution (40 parts) containing povidone (the same amount as scutellarin) under ultrasonic conditions to obtain a scutellarin suspension.
[0043] Comparative Example 2: Weigh the scutellarin raw material, add an appropriate amount of dimethyl sulfoxide, and vortex or ultrasonicate to completely dissolve it; the above solution (1 part) is fully mixed with an aqueous solution (50 parts) containing poloxamer (drug to dispersant ratio 1:2) under high-speed shear conditions to obtain a scutellarin suspension.
[0044] Comparative Example 3: Weigh the scutellarin raw material and hydroxypropyl methylcellulose (drug to dispersant ratio of 1:4), add an appropriate amount of dimethyl sulfoxide, vortex or ultrasonicate to completely dissolve them; the above solution (1 part) is fully mixed with DCM (40 parts) under ultrasonic conditions to obtain a scutellarin suspension.
[0045] Comparative Example 4: Weigh the scutellarin raw material and polyethylene glycol (drug to dispersant ratio of 1:4), add an appropriate amount of dimethyl sulfoxide, vortex or ultrasonicate to completely dissolve them; the above solution (1 part) is fully mixed with DCM (20 parts) under ultrasonic conditions to obtain a scutellarin suspension.
[0046] Example 10: Observation of suspension morphology and storage stability.
[0047] Take the freshly prepared nanosuspension and observe its appearance immediately. After leaving it at room temperature overnight, observe it again and take pictures. Take a small amount and drop it on a glass slide, cover it with a coverslip immediately, observe the particle size, morphology and aggregation state under a microscope and take pictures.
[0048] The appearance of the suspensions of Examples 1-3 is shown in Figure 1 The results show that the fresh suspensions obtained in the above examples all have a pale yellow turbid appearance, and no stratification is observed after being left overnight. The suspensions before and after being left are in the form of nearly transparent tiny particles under a microscope with good dispersion.
[0049] The appearance of the suspensions of Comparative Examples 1-4 is shown in Figure 2The results show that the fresh suspensions obtained in the above comparative examples all have a light yellow turbid appearance, and under a microscope, obvious particles can be seen, with different morphologies and aggregation. After being left overnight, obvious stratification was observed, and under a microscope, it can be seen that the particles are enlarged and aggregated.
[0050] The above results show that the suspension particles obtained in the embodiment are small and uniform, and the initial placement stability is better.
[0051] Example 11: Particle size distribution test of suspension.
[0052] Take an appropriate amount of the freshly prepared nanosuspension of Example 1, add an appropriate amount of water to the prepared nanoparticle powder and disperse it, and then use a laser particle size analyzer to measure the particle size distribution. The results are shown in Figure 3 A, 3B. The results showed that the average particle size of the freshly prepared suspension was about 149 nm and highly uniform, and the average particle size of the dried powder after redispersion was about 700 nm and still relatively uniform, which was presumably due to a certain aggregation of the crystallized particles during the drying process.
[0053] The nanosuspensions and nanoparticle powders prepared in other examples were taken to measure the average particle sizes, and the results are shown in Table 1.
[0054] Table 1 The average particle size of the samples obtained in each example
[0055] Example No. Average particle size of nanosuspension, nm Average particle size of nanoparticle powder redispersed, nm 2 592.88 833.83 3 320.89 844.28 4 490.14 856.41 5 574.33 790.52 6 765.22 988.37 7 463.80 865.85 8 679.20 917.07 9 496.31 868.55
[0056] The results in Table 1 show that the above embodiments can prepare a suspension with an average particle size of less than 800 nm, and the average particle size obtained after redispersion after drying is still less than 1000 nm, and the redispersion performance is excellent.
[0057] Example 12: Observation of particle microscopic morphology.
[0058] The relevant samples were observed under a scanning electron microscope. Figure 3 C-3F. The results showed that the breviscapine raw material ( Figure 3 C) is in irregular block shape with a particle size greater than 20 μm; the nanosuspension obtained in Example 1 ( Figure 3 D) is a loose aggregate containing a large number of adhered fine particles, and the diameter of a single particle is less than 0.5μm. It is speculated that during the sample preparation process, the suspension was directly dropped on the sample table and evaporated naturally. As the solvent evaporated, the particles gradually aggregated and accumulated; the nano dry powder obtained in Example 1 ( Figure 3 E) is irregular and dense. After magnification ( Figure 3 F) A large number of fine particles were observed, with the diameter of individual particles being less than 0.5 μm, which was presumably due to pulverization after concentration and drying.
[0059] Example 13: Characterization of properties of Breviscapine nanoparticle powder
[0060] Take an appropriate amount of the nanoparticle powder obtained in Example 1 and scan it with a powder X-ray diffractometer (PXRD). The measurement conditions are: scanning angle 2θ, step length 0.02°, scanning speed 8° / min, and scanning range 5 ~ 60°. The results are shown in Figure 4 A. The results showed that the characteristic peaks of the product formed in Experimental Example 1 almost completely disappeared, confirming that it was in an amorphous state; while the breviscapine raw material and its physical mixture with povidone both showed characteristic diffraction peaks, confirming that they were in a crystalline state.
[0061] Take an appropriate amount of the nanoparticle powder obtained in Example 1 and scan it with a differential scanning calorimeter (DSC). The measurement conditions are: using a blank crucible as a reference, heating rate 10°C / min, test temperature range 30-400°C, testing under nitrogen protection conditions, and air flow rate 20mL / min. The results are shown in Figure 4 B. The results show that the product obtained in Experimental Example 1 has no obvious endothermic or exothermic peaks, and may be amorphous; while the scutellarin raw material has endothermic peaks at 139°C and 198°C, and an exothermic peak at 212.8°C, indicating that it is crystalline; the physical mixture of scutellarin and povidone still has an endothermic peak at about 200°C, indicating that the two have a potential interaction during the test, but are still in a certain crystalline state.
[0062] Example 14: Determination of equilibrium solubility of breviscapine nanoparticle powder
[0063] The equilibrium solubility of scutellarin in the nanoparticle powder obtained in Example 1 of the present invention was investigated: excess scutellarin raw material drug and scutellarin nanoparticle powder were taken respectively, an appropriate amount of solvent was added, and the mixture was placed in a constant temperature air bath shaker (37°C, 120 r / min), shaken for 48 h, taken out and immediately centrifuged, the supernatant was taken, diluted with the corresponding solvent, and the absorption peak area was determined by HPLC, and the equilibrium solubility of scutellarin was calculated. The results are as follows: Figure 4 C. The results showed that the drug solubility of breviscapine dry nanoparticle powder in pure water was 5.8 times that of the raw drug, and the water solubility was significantly improved.
[0064] Example 15: Evaluation of in vitro dissolution performance of breviscapine
[0065] The paddle method was used for testing, the release medium was water, the temperature was (37±0.5°C), and the rotation speed was 50rpm / min; a small amount of breviscapine and an equivalent amount of physical mixture and nanoparticle powder (Example 1) were accurately weighed in 900mL of the medium, 2mL was sampled at each predetermined time point, passed through a 0.22μm microporous filter membrane, and an isothermal and equal volume of dissolution medium was added at the same time; the absorption peak area was determined by HPLC, the cumulative dissolution rate in each time period was calculated, and the dissolution curve was drawn. The results are as follows: Figure 4D (Mean±SD, n=3). The results showed that the in vitro dissolution of scutellarin raw materials was slow, with a cumulative dissolution rate of less than 20% at 60 min; the dissolution of scutellarin in the physical mixture of scutellarin and povidone was accelerated, with a dissolution rate of about 24% in 5 min and a cumulative dissolution of less than 35% at 60 min; while the dissolution rate of scutellarin in scutellarin nanoparticles was high and the dissolution speed was extremely fast, with a dissolution rate of more than 50% at 1 min and equilibrium reached in 5 min. The drug loading of scutellarin nanoparticle powder was measured to be more than 40%, showing a significant effect on promoting the in vitro dissolution of the poorly soluble drug scutellarin.
[0066] The above description shows and describes several preferred embodiments of the present invention, but as mentioned above, it should be understood that the present invention is not limited to the form disclosed herein, and should not be regarded as excluding other embodiments, but can be used in various other combinations, modifications and environments, and can be modified within the scope of the invention concept described herein through the above teachings or the technology or knowledge of the relevant field. Changes and variations made by those skilled in the art do not depart from the spirit and scope of the present invention, and should be within the scope of protection of the claims attached to the present invention.
Claims
1. A method for preparing breviscapine nanoparticle powder with good redispersibility after drying, characterized in that: The scutellarin nanoparticle powder is composed of scutellarin and a dispersant, the weight ratio of scutellarin to the dispersant is 1:1, and the dispersant is poloxamer; The breviscapine nanopowder is in an amorphous state and has no obvious characteristic diffraction peaks when detected by a powder X-ray diffractometer; The preparation method is an anti-solvent precipitation method, wherein scutellarin is dissolved in a good solvent, a dispersant is dissolved in a poor solvent, a method selected from vortexing, stirring, ultrasound, and high-speed shearing is used to assist in dispersing the scutellarin solution in the poor solvent, the poor solvent is recovered after concentration, and the solution is dried under reduced pressure at 60° C. The good solvent used in the preparation process is dimethyl sulfoxide; the poor solvent used is dichloromethane.
2. The method for preparing breviscapine nanoparticle powder according to claim 1, characterized in that: The average particle size of the nanoparticle powder after adding water and redispersing is less than 1000 nm.
